Literature DB >> 11709608

Association of clinical, radiological and synovial immunopathological responses to anti-rheumatic treatment in rheumatoid arthritis.

A R Pettit1, H Weedon, M Ahern, S Zehntner, I H Frazer, J Slavotinek, V Au, M D Smith, R Thomas.   

Abstract

OBJECTIVES: To compare immunohistochemical scoring with clinical scoring and radiology for the assessment of rheumatoid arthritis (RA) disease activity, synovial tissue (ST) biopsied arthroscopically was assessed from 18 patients before and after commencement of disease-modifying anti-rheumatic drug (DMARD) therapy.
METHODS: Lymphocytes, macrophages, differentiated dendritic cells (DC), vascularity, tumour necrosis factor (TNF) alpha and interleukin-1beta levels were scored. Clinical status was scored using the American College of Rheumatology (ACR) core set and serial radiographs were scored using the Larsen and Sharp methods. Histopathological evidence of activity included infiltration by lymphocytes, DC, macrophages, tissue vascularity, and expression of lining and sublining TNFalpha. These indices co-varied across the set of ST biopsies and were combined as a synovial activity score for each biopsy.
RESULTS: The change in synovial activity with treatment correlated with the ACR clinical response and with decreased radiological progression by the Larsen score. The ACR response to DMARD therapy, the change in synovial activity score and the slowing of radiological progression were each greatest in patients with high initial synovial vascularity.
CONCLUSIONS: The data demonstrate an association between clinical, radiological and synovial immunopathological responses to anti-rheumatic treatment in RA. High ST vascularity may predict favourable clinical and radiological responses to treatment.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11709608     DOI: 10.1093/rheumatology/40.11.1243

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  6 in total

1.  Synovial tissue macrophages: a sensitive biomarker for response to treatment in patients with rheumatoid arthritis.

Authors:  J J Haringman; D M Gerlag; A H Zwinderman; T J M Smeets; M C Kraan; D Baeten; I B McInnes; B Bresnihan; P P Tak
Journal:  Ann Rheum Dis       Date:  2004-12-02       Impact factor: 19.103

2.  The needle and the damage done.

Authors:  J K Franz; G-R Burmester
Journal:  Ann Rheum Dis       Date:  2005-06       Impact factor: 19.103

Review 3.  Cells of the synovium in rheumatoid arthritis. Dendritic cells.

Authors:  Viviana Lutzky; Suad Hannawi; Ranjeny Thomas
Journal:  Arthritis Res Ther       Date:  2007       Impact factor: 5.156

Review 4.  Osteoimmunology: Major and Costimulatory Pathway Expression Associated with Chronic Inflammatory Induced Bone Loss.

Authors:  Tania N Crotti; Anak A S S K Dharmapatni; Ekram Alias; David R Haynes
Journal:  J Immunol Res       Date:  2015-05-03       Impact factor: 4.818

Review 5.  Old drugs, old problems: where do we stand in prediction of rheumatoid arthritis responsiveness to methotrexate and other synthetic DMARDs?

Authors:  Vasco Crispim Romão; Helena Canhão; João Eurico Fonseca
Journal:  BMC Med       Date:  2013-01-23       Impact factor: 8.775

6.  Rheumatoid arthritis synovium contains plasmacytoid dendritic cells.

Authors:  Lois L Cavanagh; Amanda Boyce; Louise Smith; Jagadish Padmanabha; Luis Filgueira; Peter Pietschmann; Ranjeny Thomas
Journal:  Arthritis Res Ther       Date:  2005-01-11       Impact factor: 5.156

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.